517 related articles for article (PubMed ID: 25936229)
1. Selective estrogen receptor modulators in clinical practice: a safety overview.
Ellis AJ; Hendrick VM; Williams R; Komm BS
Expert Opin Drug Saf; 2015 Jun; 14(6):921-34. PubMed ID: 25936229
[TBL] [Abstract][Full Text] [Related]
2. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
3. Use of SERMs for treatment in postmenopausal women.
Pinkerton JV; Thomas S
J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
[TBL] [Abstract][Full Text] [Related]
4. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
5. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
6. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.
Maximov PY; Lee TM; Jordan VC
Curr Clin Pharmacol; 2013 May; 8(2):135-55. PubMed ID: 23062036
[TBL] [Abstract][Full Text] [Related]
7. Selective estrogen modulators in menopause.
Gambacciani M
Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
[TBL] [Abstract][Full Text] [Related]
8. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development.
Gennari L; Merlotti D; Valleggi F; Martini G; Nuti R
Drugs Aging; 2007; 24(5):361-79. PubMed ID: 17503894
[TBL] [Abstract][Full Text] [Related]
9. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.
Gennari L
Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439
[TBL] [Abstract][Full Text] [Related]
10. The future of the new selective estrogen receptor modulators.
Palacios S
Menopause Int; 2007 Mar; 13(1):27-34. PubMed ID: 17448265
[TBL] [Abstract][Full Text] [Related]
11. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
DeGregorio MW; Zerbe RL; Wurz GT
Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
[TBL] [Abstract][Full Text] [Related]
12. An overview of current and emerging SERMs.
Komm BS; Mirkin S
J Steroid Biochem Mol Biol; 2014 Sep; 143():207-22. PubMed ID: 24667357
[TBL] [Abstract][Full Text] [Related]
13. Tissue-selective estrogen complexes for postmenopausal women.
Mirkin S; Komm BS
Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
[TBL] [Abstract][Full Text] [Related]
14. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland.
Peano BJ; Crabtree JS; Komm BS; Winneker RC; Harris HA
Endocrinology; 2009 Apr; 150(4):1897-903. PubMed ID: 19022889
[TBL] [Abstract][Full Text] [Related]
15. Selective estrogen-receptor modulators in 2001.
O'Regan RM; Gradishar WJ
Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
[TBL] [Abstract][Full Text] [Related]
16. Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators.
Pinkerton JV; Conner EA
Climacteric; 2019 Apr; 22(2):140-147. PubMed ID: 30895900
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor modulators: the future in menopausal treatment.
Palacios S
Minerva Ginecol; 2011 Jun; 63(3):275-86. PubMed ID: 21654612
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
Wurz GT; Kao CJ; DeGregorio MW
Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
[TBL] [Abstract][Full Text] [Related]
19. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
20. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
